Hero

Press Releases

Press Releases

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, NY, September 6, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 17th Annual BioPharma Conference on Thursday, September 8 at 11:20 a.m.

Royalty Pharma Reports Second Quarter 2022 Results

NEW YORK, NY,  August 04, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2022 and raised full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).

Royalty Pharma Declares Third Quarter 2022 Dividend

NEW YORK, NY, July 15, 2022 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on September 15, 2022, to shareholders of record at the close of business

Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022

NEW YORK, NY, July 14, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

Royalty Pharma Agrees to Acquire Royalty Interest in Trelegy Ellipta From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

NEW YORK, July 13, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has agreed to acquire a royalty interest in Trelegy Ellipta (Trelegy) from Theravance Biopharma, Inc. (Nasdaq: TBPH) and Innoviva, Inc. (Nasdaq: INVA) for $1.31 billion in cash up front and up to 

Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

NEW YORK, NY, June 30, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million

Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

NEW YORK, NY, June 8, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43 rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET.

Royalty Pharma to Present at the UBS Global Healthcare Conference 2022

NEW YORK, NY, May 23, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. ET. The webcast will be accessible from Royalty

Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders

NEW YORK, NY, May 17, 2022 – Royalty Pharma plc (Nasdaq: RPRX) will host its inaugural Investor Day in New York City today. Royalty Pharma’s management team will provide an update on the company’s capital deployment

Royalty Pharma Reports First Quarter 2022 Results

NEW YORK , NY,  May 05, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).
Displaying 1 - 10 of 98